GLP-1 Drugs: Standards Behind Safety and Quality
GLP-1 receptor agonists have become some of the most widely discussed prescription drugs in the world. Approximately 12% of US adults have ever taken a GLP-1 drug, and 6% are currently taking a GLP-1 drug. While much attention focuses on their effectiveness for diabetes, heart disease, and weight management, fewer people realize that these medications rely on an extensive framework of international standards governing pharmaceutical manufacturing, injection devices, laboratory testing, packaging, quality management, and regulatory compliance.
What Are GLP-1s?
GLP-1s (short for “glucagon-like peptide-1 receptor agonists”) are medications that mimic a natural hormone in the body that helps to regulate blood sugar levels and appetite. Glucagon-like peptide-1 is a naturally occurring hormone produced in the intestines that plays a role in regulating blood sugar levels, appetite, and weight.
By stimulating insulin release and inhibiting glucagon secretion, GLP-1 regulates blood sugar levels and plays a role in appetite and satiety. As such, this hormone is a key target for managing type 2 diabetes and helping treat obesity.
How Do GLP-1 Drugs Work?
GLP-1 drugs work by mimicking a natural gut hormone to release insulin, slow digestion, and reduce appetite. These medications bind to cellular receptors throughout the body to control blood sugar and hunger.
What Are the Functions of GLP-1?
Here is a detailed breakdown of GLP-1s various functions:
Blood Sugar Regulation
- Stimulates insulin secretion: GLP-1 enhances insulin release from the pancreas in a glucose-dependent manner, meaning it only stimulates insulin when blood sugar levels are elevated.
- Inhibits glucagon secretion: GLP-1 reduces glucagon release from the pancreas, which helps to lower blood sugar levels by preventing the liver from releasing excess glucose.
- Improves insulin sensitivity: GLP-1 can also improve insulin sensitivity, meaning the body’s cells are better able to respond to insulin and utilize glucose.
Appetite and Digestion
- Slows Gastric Emptying: GLP-1 delays the rate at which food leaves the stomach, which can help to prevent rapid spikes and drops in blood sugar levels after meals.
- Promoted Satiety: GLP-1 increases feelings of fullness and reduces appetite, leading to decreased food intake.
- Reduces Food Intake: By slowing down digestion and promoting satiety, GLP-1 helps to regulate food intake and potentially aids in weight management.
Other Potential Benefits
- Cardiovascular Protection: GLP-1 agonists have shown promising cardiovascular benefits, including improved left ventricular ejection fraction, myocardial contractility, and reduced infarction size.
- Neuroprotection: GLP-1 may have neuroprotective effects, potentially reducing oxidative stress and inflammation in the brain.
- Beta-Cell Protection: GLP-1 can protect pancreatic beta cells (which produce insulin) from damage and promote their growth and differentiation.
It is important to note that GLP-1 medications are relatively new. The U.S. Food and Drug Administration (FDA) approved the first GLP-1 agonist (exenatide) in 2005, and researchers are still learning about their other potential uses and benefits. Additionally, GLP-1 agonists alone cannot treat Type 2 diabetes or obesity as both conditions require other treatment strategies like lifestyle and dietary changes.
Examples of GLP-1 Agonists
GLP-1 receptor agonists (GLP-1RAs) are a class of medications that mimic the effects of GLP-1. They are used mainly to help managed blood sugar (glucose levels) to treat type 2 diabetes and obesity. GLP-1 agonists help to improve blood sugar control, promote weight loss, and reduce the risk of cardiovascular events in people with diabetes. Here are examples of GLP-1 agonists:
- Dulaglutide
- Exenatide
- Exenatide Extended-Release
- Liraglutide
- Lixisenatide
- Semaglutide
- Tirzepatide
“GLP-1 receptor agonists (GLP-1RAs)” and “GLP-1 agonists” are essentially the same thing, referring to the same class of medications that mimic the effects of the natural hormone GLP-1.
How Good Laboratory Practice (GLP) Relates to GLP-1
GLP stands for Good Laboratory Practice: a quality system guideline covering the organizational processes and conditions under which non-clinical laboratory studies are planned, performed, monitored, recorded, reported, and retained (or archived). GLP provides the framework and standards for conducting high-quality, reliable non-clinical studies, which are essential for the development and approval of GLP-1 drugs and other regulated products.
GLP helps to assure that the efficiency of GLP-1 drugs in treating diabetes and obesity is accurately assessed in non-clinical studied drugs. ISO/IEC 17025 is relevant for laboratories conducting safety and efficacy testing because it outlines general requirements for the competence of testing and calibration laboratories. This international standard provides a framework for assuring the quality and reliability of laboratory operations.
GLP compliance is a requirement for submitting non-clinical data to regulatory agencies for approval of GLP-1 drugs.
International Standards and Their Requirements for GLP-1 Drug Delivery Devices
International standards provide a unified framework for GLP-1 delivery devices, which are primarily injectable pen devices (autoinjectors or pen injectors)—with some options available as oral tablets. Standardizing materials and processes simplify the manufacturing process and reduces the risk of non-compliance during regulatory assessments. Some specific specifications and standardizations that relate to GLP-1 drug delivery devices are as follows:
ISO 14644-1:2015, Cleanrooms and associated controlled environments – Part 1: Classification of air cleanliness by particle concentration Cleanroom Standards
The manufacturing facilities for GLP-1 receptor agonist medications (such as injectable peptides) can adhere to ISO 14644-1, which establishes requirements for cleanroom classification, monitoring, and control. This international standard helps manufacturers maintain environments suitable for sterile pharmaceutical production.
ISO 11608-1:2022, Needle-based injection systems for medical use – Requirements and test methods – Part 1: Needle-based injection systems
ISO 11608-1 specifies requirements for needle-based injection systems, focusing on safety, usability, and dose accuracy. Furthermore, the ISO 11608 series specifies requirements and test methods for devices such as pen injectors, including dose accuracy, functionality, and performance.
ISO 11040-1:2015, Prefilled syringes – Part 1: Glass cylinders for dental local anaesthetic cartridges
ISO 11040-1 addresses specifications for prefilled syringes, assuring compatibility and performance.
ISO 11607-1:2019, Packaging for terminally sterilized medical devices – Part 1: Requirements for materials, sterile barrier systems and packaging systems
ISO 11607-1 specifies requirements and test methods for sterile barrier systems and packaging, assuring devices maintain sterility until use.
Standards Supporting the Safety and Quality of GLP-1 Medications
As GLP-1 medications continue to transform the treatment landscape for diabetes and obesity, standards play a critical role in harmonizing the design and production processes across markets around the world while also maintaining safety. International standards such as ISO 14644-1 for cleanroom environments, ISO/IEC 17025 for laboratory competence, and ISO 11608-1 for needle-based injection systems help organizations establish processes that promote product quality, performance, and patient safety.
